Document Detail


Mycophenolate mofetil in the treatment of ocular inflammation in ANCA-associated vasculitis.
MedLine Citation:
PMID:  18321200     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
AIM: The aim of this study was to describe the use of mycophenolate mofetil (MMF) in the treatment of patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis with ocular involvement.
METHODS: A retrospective review was performed. Ocular and systemic manifestations, history of previous immunosuppressive drug therapy, concurrent therapy with MMF, response to treatment, side effects related to the use of MMF, and follow-up period were recorded.
RESULTS: Nine (9) eyes of 5 patients were evaluated. Ocular involvement included scleritis, choroidal and orbital granuloma, multifocal choroiditis, intermediate uveitis, and lacrimal gland involvement. Mycophenolate was started at 2 g daily. Mean follow-up after the initiation of MMF was 36 months. Mean prednisolone dose at onset of treatment with MMF was 27 mg daily and was reduced to 7 mg daily as disease control was achieved. Visual acuity was maintained or improved in all eyes, apart from 1 eye, which developed cataract formation. One (1) patient required a reduction in the dose of mycophenolate owing to diarrhea.
CONCLUSIONS: Our study suggests that mycophenolate mofetil may be a safe, effective therapeutic modality for ocular inflammation associated with ANCA-associated vasculitis.
Authors:
F Nilüfer Yalçindağ; Radgonde Amer; John V Forrester
Publication Detail:
Type:  Case Reports; Journal Article    
Journal Detail:
Title:  Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics     Volume:  24     ISSN:  1080-7683     ISO Abbreviation:  J Ocul Pharmacol Ther     Publication Date:  2008 Apr 
Date Detail:
Created Date:  2008-04-24     Completed Date:  2008-06-24     Revised Date:  2013-05-29    
Medline Journal Info:
Nlm Unique ID:  9511091     Medline TA:  J Ocul Pharmacol Ther     Country:  United States    
Other Details:
Languages:  eng     Pagination:  249-54     Citation Subset:  IM    
Affiliation:
Department of Ophthalmology, University of Aberdeen Medical School, Aberdeen, UK. yalcinda@medicine.ankara.edu.tr
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Anti-Inflammatory Agents / therapeutic use
Anti-Inflammatory Agents, Non-Steroidal / administration & dosage,  adverse effects,  therapeutic use*
Antibodies, Antineutrophil Cytoplasmic / immunology
Cataract / etiology
Diarrhea / chemically induced
Eye Diseases / drug therapy*,  etiology
Female
Follow-Up Studies
Humans
Middle Aged
Mycophenolic Acid / administration & dosage,  adverse effects,  analogs & derivatives*,  therapeutic use
Prednisolone / therapeutic use
Retrospective Studies
Vasculitis / drug therapy*,  immunology,  physiopathology
Visual Acuity / drug effects
Chemical
Reg. No./Substance:
0/Anti-Inflammatory Agents; 0/Anti-Inflammatory Agents, Non-Steroidal; 0/Antibodies, Antineutrophil Cytoplasmic; 24280-93-1/Mycophenolic Acid; 50-24-8/Prednisolone; 9242ECW6R0/mycophenolate mofetil

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Successful treatment of postoperative fungal endophthalmitis using intravitreal and intracameral vor...
Next Document:  Redox signaling, vascular function, and hypertension.